SynthesisBMC cancer2025
Mitochondrial DNA mutations in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Coptisine suppresses oral squamous cell carcinoma via regulating the JAK2/STAT3 to induce mitochondrial dysfunction in cancer cells and promote macrophage polarization to M1.American journal of cancer research · 2026Article
- Mitochondrial-targeted therapeutics in oral squamous cell carcinoma: molecular and therapeutic implications.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) cause approximately 95% of head and neck malignancies. Clinicopathological predictions are limited, and mitochondrial DNA (mtDNA) mutations have emerged as possible biomarkers. This systematic review and meta-analysis aimed to quantify the relative contributions of several mitochondrial genome regions to the overall mutational burden in HNSCC, thereby contextualizing their potential biological importance. MATERIALS AND
methodsA systematic review and meta-analysis were conducted in accordance with the PRISMA criteria. PubMed, EMBASE, Scopus, and Web of Science were searched up to May 2025. Eligible studies reporting somatic mtDNA mutations in HNSCC were included. The quality of included studies was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. Proportional meta-analyses under random-effects models determined pooled mutation shares for six mtDNA regions.
resultsSeventeen studies were included. The D-loop was the major hotspot (67%, 95% CI: 0.28-0.91; I
conclusionThe D-loop and ND genes dominate the mutational spectrum of HNSCC. While these findings highlight recurrent alternations in mtDNA, further studies are required to evaluate their potential as a biomarker for diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.